Loperamide treatment of the irritable bowel syndrome
- PMID: 3306904
- DOI: 10.3109/00365528709091004
Loperamide treatment of the irritable bowel syndrome
Abstract
The effect of loperamide was investigated in a double-blind, placebo-controlled study in 60 patients with irritable bowel syndrome (IBS). Active treatment was given in low dosage (4 mg nocte). The effect of treatment was assessed in clinical subgroups. In a group of patients with painless diarrhoea (n = 16) there was a highly significant improvement in stool frequency and consistency. In a group with alternating bowel habits and abdominal pain (n = 21) there was also a statistically significant improvement in stool frequency and consistency as well as significantly fewer painful days during loperamide treatment. Patients with alternating bowel habits and no pain (n = 12) experienced no symptomatic improvement, and patients with constipation (n = 9) generally felt worse on loperamide. No side effects were encountered. It is concluded that loperamide can be considered an alternative symptomatic treatment in some IBS patients whose main symptoms are painless diarrhoea or alternating bowel habits associated with abdominal pain.
Similar articles
-
Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study.Scand J Gastroenterol Suppl. 1987;130:77-80. doi: 10.3109/00365528709091003. Scand J Gastroenterol Suppl. 1987. PMID: 3306903 Clinical Trial.
-
Role of loperamide and placebo in management of irritable bowel syndrome (IBS).Dig Dis Sci. 1984 Mar;29(3):239-47. doi: 10.1007/BF01296258. Dig Dis Sci. 1984. PMID: 6365490 Clinical Trial.
-
A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome.Scand J Gastroenterol. 1996 May;31(5):463-8. doi: 10.3109/00365529609006766. Scand J Gastroenterol. 1996. PMID: 8734343 Clinical Trial.
-
Review article: clinical evidence to support current therapies of irritable bowel syndrome.Aliment Pharmacol Ther. 1999 May;13 Suppl 2:48-53. Aliment Pharmacol Ther. 1999. PMID: 10429740 Review.
-
Therapeutic strategy for the irritable bowel syndrome.Ital J Gastroenterol. 1991 Nov;23(8 Suppl 1):53-5. Ital J Gastroenterol. 1991. PMID: 1661628 Review.
Cited by
-
Diagnosis and management of IBS.Nat Rev Gastroenterol Hepatol. 2010 Oct;7(10):565-81. doi: 10.1038/nrgastro.2010.137. Nat Rev Gastroenterol Hepatol. 2010. PMID: 20890316 Review.
-
Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits.Clin Gastroenterol Hepatol. 2017 Sep;15(9):1338-1349. doi: 10.1016/j.cgh.2017.05.014. Epub 2017 May 19. Clin Gastroenterol Hepatol. 2017. PMID: 28529168 Free PMC article. Review.
-
Evidence-based clinical practice guidelines for irritable bowel syndrome 2020.J Gastroenterol. 2021 Mar;56(3):193-217. doi: 10.1007/s00535-020-01746-z. Epub 2021 Feb 4. J Gastroenterol. 2021. PMID: 33538894 Free PMC article.
-
Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use.Am J Gastroenterol. 2017 Jun;112(6):924-932. doi: 10.1038/ajg.2017.72. Epub 2017 Apr 18. Am J Gastroenterol. 2017. PMID: 28417992 Free PMC article. Clinical Trial.
-
Management Options for Irritable Bowel Syndrome.Mayo Clin Proc. 2018 Dec;93(12):1858-1872. doi: 10.1016/j.mayocp.2018.04.032. Mayo Clin Proc. 2018. PMID: 30522596 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical